Also from this source


You just read:

Positive Phase 2b Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

News provided by

Pharmalink AB

May 31, 2017, 03:41 ET